Could NDC-1308 be a new hope for secondary progressive MS?

[MSUK]

ENDECE Neural announced the presentation of new, pre-clinical evidence that the company’s lead compound, NDC-1308, induces remyelination and increases forelimb grip strength in a validated animal model of demyelination. As presented in a poster session at the 2014 annual meeting of the Society for Neuroscience in Washington, D.C., the improvements with NDC-1308 therapy are linked to the drug’s unique ability to repair the myelin sheath of demyelinated axons (nerve fibres).

The data, presented by Steven H. Nye, Ph.D., Vice President of Discovery at ENDECE Neural, suggest that the remyelinating properties of NDC-1308 may benefit patients with secondary progressive multiple sclerosis (SPMS). ENDECE Neural has announced plans to initiate non-clinical investigational new drug (IND)-enabling studies of NDC-1308 and a first-in-humans Phase 1 clinical trial in 2015....... Read More - http://www.ms-uk.org/emergingtherapies